ArticleBMC research notes2025
Bioluminescent monitoring of a co-culture model of pathogen growth to identify a novel probiotic bacterium.
Article in BMC research notes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectiveProbiotic bacteria can inhibit the growth of harmful bacterial species but may be limited in the bacteria they can counteract. We developed a novel co-culture assay in which candidate probiotic bacteria can be co-incubated with both Gram-positive and Gram-negative reporter pathogens that have been modified to emit light, so as to monitor pathogen growth simply by quantitation of emitted light from the culture. We used this assay to identify a novel probiotic bacterium with anti-microbial activity against both Gram-positive and Gram-negative pathogens.
resultsWe isolated a novel bacterium from non-pasteurized milk and identified it as a strain of Lactobacillus delbrueckii. Testing in our assay confirmed that this bacterium was able to inhibit the growth of both Staphylococcus aureus and Escherichia coli, but in a delayed fashion, after allowing a period of early growth. This activity was not dependent on living cells but also a property of conditioned medium. We posited that this was because the pathogens stimulated the production of an inhibitory factor from the Lactobacillus, presumably a bacteriocin peptide. Pre-treatment of conditioned medium with a protease abolished this inhibitory activity, indicating that L. delbrueckii is stimulated to produce an antibacterial peptide in the presence of a bacterial pathogen.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.